Zentek Ltd. (CVE:ZEN – Free Report) – Atrium Research issued their Q2 2027 earnings per share (EPS) estimates for shares of Zentek in a report issued on Monday, September 14th. Atrium Research analyst B. Pirie forecasts that the mining company will post earnings of ($0.01) per share for the quarter. Atrium Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Zentek’s current full-year earnings is ($0.10) per share. Atrium Research also issued estimates for Zentek’s Q3 2027 earnings at ($0.01) EPS, Q4 2027 earnings at ($0.01) EPS, FY2027 earnings at ($0.05) EPS and FY2028 earnings at ($0.05) EPS.
Zentek Stock Performance
Shares of ZEN opened at C$0.77 on Wednesday. The company has a debt-to-equity ratio of 7.62, a current ratio of 4.65 and a quick ratio of 7.59. Zentek has a one year low of C$0.52 and a one year high of C$1.50. The stock has a 50-day moving average of C$0.78 and a 200-day moving average of C$0.77. The company has a market cap of C$97.50 million, a PE ratio of -7.94 and a beta of 0.33.
About Zentek
Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds. It is also developing graphene oxide synthesis and graphene synthesis. In addition, the company owns 100% interest in the Albany graphite project located in Northern Ontario, Canada.
See Also
- Five stocks we like better than Zentek
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Zentek Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentek and related companies with MarketBeat.com's FREE daily email newsletter.
